High Health Spending In The U.S. Isn't Being Driven By Low Social Spending
(8/15, Going Below the Surface) comments “The United States has the highest per-capita rate of health care spending in the world, and the country's status as an international outlier has been linked to a perceived under-investment in social programs, such as employment, housing and education, which, in turn, has been theorized to harm health outcomes and drives health spending. But a new study in Health Affairs – part of the National Pharmaceutical Council- and Anthem, Inc.-sponsored ‘Considering Health Spending’ series – calls into question the idea that increased social spending will pay for itself in lower health care bills.” Full
The U.S. Doesn't Spend Less on Social Care than Other Developed Countries
(8/15, Caitlin Owens, Axios) comments “...The big picture: Some policymakers and researchers say that the underinvestment in social services has led to a less healthy population, and point to the low U.S. ratio of social-to-health spending. Between the lines: Instead, our spending on social services as a percentage of GDP is actually greater than the average of OECD countries, and there's a positive correlation between a country's spending on social services and its spending on health care.” Full
Outcomes-Based Pricing: Can It Facilitate The Study Of Precision Dosing?
(8/14, Michael Cipriano, Pink Sheet) reports “...‘Outcomes-based pricing, my goodness,’ [Richard Peck, global head or clinical pharmacology at Roche,] said. ‘If there's outcomes-based pricing, people like my colleagues are really going to want to know, we only want to dose the right patients, and we really need to give you the right dose because we don't want you to not to have efficacy because we didn't give you enough. And we don't want you not to have efficacy because we gave you too much and you have side effects and stop taking the drug. And so that's an enormous incentive.’” Paid Subscription Required
The Real-World Evidence Project at the FDA Adds Syapse to its List of Partners in a Push past Trial Boundaries
(8/15, John Carroll, Endpoints News) reports “...‘Advancing a deeper understanding of real-world endpoints and analytical methodologies is critical to assuring that all stakeholders can have confidence in the quality of evidence produced and accelerating the use of RWE in regulatory decision-making,’ noted company founder and president Jonathan Hirsch in a prepared statement. ‘The network of health systems that Syapse represents offers a unique opportunity to learn from oncology patient journeys and populations not well represented in traditional clinical trials.’” Full
Real-World Data in the Era of Precision Medicine for Lymphoid Malignancies
(8/15, Caleb Rans, PharmD, Hematology Advisor) reports “Until recently, treatment strategies for lymphoma have been largely based on cell morphology. At present, standardized treatment approaches are common, despite ongoing advances in precision medicine for lymphoid malignancies. As the field of precision medicine continues to advance, the utility of real-world data to support the development of improved therapies for lymphoma is becoming increasingly evident.” Full
Leaders of NIH's All of Us Research Program Recap Progress and Next Steps
(8/14, National Institutes of Health Press Release) “The All of Us Research Program at the National Institutes of Health has made strong progress in its efforts to advance precision medicine, according to program leadership in a forthcoming paper in the New England Journal of Medicine.” Full
The Relationship Between Health Spending And Social Spending In High-Income Countries: How Does The US Compare?
Irene Papanicolas, et al.
August 14, 2019, Health Affairs
Doctors Should Treat Impetigo with Antiseptics Not Antibiotics, Says NICE
August 15, 2019, BMJ
Cost Effectiveness of Interventions to Improve Adherence to Statin Therapy in ASCVD Patients in the United States
Armstrong SO, Little RA
August 15, 2019, Patient Preference and Adherence
Patient Preference and Adherence
Ataluren Use in Patients with Nonsense Mutation Duchenne Muscular Dystrophy: Patient Demographics and Characteristics from the STRIDE Registry
Francesco Muntoni, et al.
August 15, 2019, The Journal of Comparative Effectiveness Research
The Journal of Comparative Effectiveness Research